

Member FINRA/SIPC

Toll-Free: 561-391-5555 • www.DawsonJames.com • 101 North Federal Highway - Suite 600 • Boca Raton, FL 33432

## 22nd Century Group, Inc. (AMEX: XXII)

April 13, 2021

### BUY: Expect Multiple Catalysts this Year

*We believe multiple catalysts this year could drive 22nd Century shares higher. The most likely near-term catalyst is approval of the company's MRTP application with the FDA. Second, the company believes it can begin monetizing its hemp intellectual property this year with one or more licensing deals of plants with specific combinations of cannabinoids. The revivification of the low-nicotine mandate appears possible this year. Also, the company plans to announce development of a third, plant-based franchise after its MRTP application is approved.*

**MRTP Approval Pending:** It has been just over a year since the company presented to the Tobacco Products Scientific Advisory Committee (TPSAC), and with the pandemic receding and a new administration implementing its policies, we believe conditions are favorable for approval. The company is committed to a commercial launch of VLN cigarettes within 90 days of MRTP approval and is in active discussions with retailers and distributors. The initial stage will be to select markets to test customer acceptance, pricing, and marketing. This will continue for a few months and be recalibrated as the roll-out expands.

**Monetizing Hemp.** Monetizing its hemp IP this year would be sooner than we have modeled and be positive for the stock. Over the past quarters, the company has re-positioned itself to better address the upstream portion of the market where its expertise in plant genetics can be more efficiently applied. Hemp, and ultimately, recreational cannabis, when legal at the federal level, would be significant sources of revenue and value for the company.

**A Low-Nicotine Mandate.** The FDA began an Advanced Notice of Proposed Rulemaking (ANPRM) in 2018 that would have required non-addictive nicotine levels in combustible cigarettes. A change in regulatory policy by the federal government and the resignation of the FDA commissioner could have been key factors in the initiative not moving forward, but we believe the goal is still alive and a new administration could revive the mandate in the coming quarters.

**Valuation:** Our \$7 price target is the sum of the estimated values of the VLN, non-addictive nicotine and hemp franchises. We attribute about \$3.08/share for the VLN asset. The non-addictive nicotine mandate is valued at \$3.18 per share. The remainder of the price target comprises the investment in the hemp business and its relationship with KeyGene.

**Risks to Target:** The tobacco industry is highly regulated, and our price target depends on approval of the company's MRTP application and a nicotine mandate, which could be delayed or may not be approved. Our price target assumes the company will find a partner for the VLN business and this could take longer than estimated and/or the partner could demand different terms than assumed. The nicotine mandate may take longer to decide, and the transition period could be longer than estimated. There will likely be other paths attempted by the industry to comply or the industry may opt to focus on other nicotine delivery systems as regulation of the combustible cigarette market increases. This could affect our assumptions on the royalty rate and market share.

James McIlree, CFA

866-928-0928

jmcilree@dawsonjames.com

Current Price	\$3.48		
Price Target	\$7.00		
Estimates	F2020A	F2021E	F2022E
Revenues (\$000s)	\$ 28,111	\$ 29,000	\$ 30,000
1Q March	\$ 7,058	\$ 7,250	\$ 7,500
2Q June	\$ 6,435	\$ 7,250	\$ 7,500
3Q September	\$ 7,310	\$ 7,250	\$ 7,500
4Q December	\$ 7,308	\$ 7,250	\$ 7,500
	F2020A	F2021E	F2022E
EPS (diluted)	\$ (0.14)	\$ (0.12)	\$ (0.12)
1Q March	\$ (0.03)	\$ (0.03)	\$ (0.03)
2Q June	\$ (0.04)	\$ (0.03)	\$ (0.03)
3Q September	\$ (0.03)	\$ (0.03)	\$ (0.03)
4Q December	\$ (0.05)	\$ (0.04)	\$ (0.04)
EBITDA (\$Ms)	\$ (16.0)	\$ (16.2)	\$ (16.3)
EV/EBITDA (x)	-31.3x	-30.8x	-30.8x
<b>Stock Data</b>			
52-Week Range	\$0.55 - \$4.66		
Shares Outstanding (mil.)	152.4		
Market Capitalization (mil.)	\$530		
Enterprise Value (mil.)	\$500		
Debt to Capital	2%		
Book Value/Share	\$0.32		
Price/Book	11.0x		
Average Three Months Trading Volume (K)	2,499		
Insider Ownership	2.2%		
Institutional Ownership	26.9%		
Short interest (mil.)	4.9%		
Dividend / Yield	\$0.00/0.0%		



## Investment Thesis

We believe multiple catalysts this year could drive 22nd Century shares higher. The most likely near-term catalyst is approval of the company's modified risk tobacco product (MRTP) application with the FDA. Second, the company believes it can begin monetizing its hemp intellectual property this year with one or more licensing deals of plants with specific combinations of cannabinoids. The revivification of the low-nicotine mandate appears possible this year. Also, the company plans to announce development of a third, plant-based franchise after its MRTP application is approved.


It has been just over a year since the company presented to the Tobacco Products Scientific Advisory Committee (TPSAC), and with the pandemic receding and a new administration implementing its policies, we believe conditions are favorable for approval. The company is committed to a commercial launch of VLN cigarettes within 90 days of MRTP approval and is in active discussions with retailers and distributors. The initial stage will be to select markets to test customer acceptance, pricing, and marketing. This will continue for a few months and be recalibrated as the roll-out expands.

Monetizing its hemp IP this year would be sooner than we have modeled and be positive for the stock. Over the past quarters, the company has re-positioned itself to better address the upstream portion of the market where its expertise in plant genetics can be more efficiently applied. Hemp, and ultimately, recreational cannabis, when legal at the federal level, would be significant sources of revenue and value for the company.

The FDA began an Advanced Notice of Proposed Rulemaking (ANPRM) in 2018 that would have required non-addictive nicotine levels in combustible cigarettes. A change in regulatory policy by the federal government and the resignation of the FDA commissioner could have been key factors in the initiative not moving forward, but we believe the goal is still alive and a new administration could revive the mandate in the coming quarters.

## Valuing VLN

According to the CDC, "based on 2019 data, about 34 million US adults smoke cigarettes," (<https://www.cdc.gov/tobacco/about/osh/index.htm>) and about two-thirds would like to quit (Stephen Babb, MPH; Ann Malarcher, PhD; Gillian Schauer, PhD; Kat Asman, MSPH; Ahmed Jamal, MBBS, January 6, 2017, "Quitting Smoking Among Adults — United States, 2000–2015," Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, Vol. 65 / No. 52), with more than half making some attempt to quit in the past 12 months. The ratio of smokers making some quit attempt in the past year has remained fairly stable over the past ten years.



Source: CDC. Tobacco Product Use and Cessation Indicators Among Adults — United States, 2018

The Federal Trade Commission Cigarette Report for 2018 reports 216.9 billion cigarette sticks were sold in the U.S. in 2018. At 20 cigarettes per pack and 34 million smokers, this equals daily consumption of about 0.87 packs per day. However, the impact of the very-low-nicotine-content (VLNC) cigarette is a reduction in consumption. From 22nd Century's TPSAC Briefing Document:

*independent studies of VLNC cigarettes show that daily smokers gradually reduced their cigarette consumption by as much as 50% over 20 weeks of use. (see Hatsukami, 2018; Donny, 2015). Such studies also showed that non-daily smokers reduced their cigarette consumption after extended use of VLNC cigarettes. (Shiffman, 2018).*

According to the CDC, in 2010, there were 45.4 million smokers in the U.S. Over the subsequent 10 years, the number of smokers in the U.S. declined at a 2.8% compound annual rate. If that rate continues, by 2025, the number of smokers will have declined to about 29.7 million. Assuming 50% try to quit in a year, the number of smokers who are likely customers of a VLN cigarette are approximately 14.8 million smoking 0.44 packs per day or 2.4 billion packs per year. If we assume prices rise 5% annually from the current \$3/pack rate to \$3.83 per pack, that is a potential addressable revenue (before excise taxes) of \$9.1 billion.

A modest market share would result in substantial value for the company. Currently, tobacco company stocks trade around 5x forward 12-month sales estimates (Source: FactSet consensus estimates). At this multiple, and a 3% market share of the smokers who attempt to quit (about 1.5% of the total market), the value of the VLN franchise, in 2025, would be worth close to \$1.4 billion, in our estimation. We believe a take-over would be at higher multiples due to the synergies available. Still assuming a 3% market share of the smokers who attempt to quit (1.5% of the total market), the VLN franchise in 2025 would be valued at close to \$2.0 billion if instead we capitalized sales at 7x.

**Potential VLN Franchise Values**

Market Share of Quitters	3x sales	5x sales	7x sales
0.5%	\$ 137M	\$ 228M	\$ 319M
1.0%	\$ 274M	\$ 456M	\$ 639M
2.0%	\$ 547M	\$ 912M	\$ 1,277M
3.0%	\$ 821M	\$ 1,368M	\$ 1,916M

*Source: Dawson James Securities estimates*

If the company seeks a partner to achieve these market share estimates, we think that the values above should be reduced by 30% to 50% to reflect the partner's interest. The discounted per-share value of the VLN franchise based on 5x to 7x sales in 2025E, using a 20% discount rate, 3% market share estimate and a 30% interest for a potential partner, is, at the midpoint, \$3.08 per share.

### **Valuing a Low-Nicotine Mandate**

The ANPRM has not turned into an NPRM, yet, but we believe it is still possible in the next 12 months. A new administration could be more willing to impose greater restrictions on nicotine in the pursuit of public health. We also believe the FDA is being careful in building a record to withstand the challenges a low-nicotine mandate is likely to encounter and part of that could be the approval of 22nd Century's MRTP. One of the stated objections to the mandate is it would be impossible to comply since the technology does not exist. Marketing of a VLN cigarette would obviate that argument.

Complying with a non-addictive low-nicotine mandate will be a challenge for the industry, and, as the current tobacco vendors admitted in their public comments on the ANPRM, 22nd Century has technology that could solve their problem.

The cost to comply with a mandate has been discussed publicly. For instance, the Director of Product Policy at Philip Morris International, Rolf Lutz, stated in 2016 it would cost \$10 billion to \$12 billion to extract nicotine from all its EU cigarettes. The company sold about 10 billion packs of cigarettes in the EU at that time, which is similar to the U.S. market currently. Mr. Lutz also indicated it could take up to 20 years to achieve lower nicotine levels with genetically modified plants. Using Mr. Lutz's estimate of time and money required, we believe the opportunity for 22nd Century is large.

If the FDA mandates a non-addictive level of nicotine, we expect the company to pursue a royalty and license model for its technology in addition to marketing a VLN brand on its own. The following table is based on a successful royalty/licensing model in the U.S. There are about 10 billion packs of cigarettes sold in the U.S. annually (Altira Group 2020 10K based on 20 sticks/pack) and we estimate this will decline by 2.8% annually over the next five years. We assume a 5% market share and \$0.10 per pack royalty. The table shows per-share discounted values based on different discount rates and revenue multiples. The mean of these estimates is \$3.18 per share.

### Potential Non-Addictive Nicotine Franchise Values

Per share Value: \$0.10/pack royalty; 5% share		Discount Rate	
		15%	20%
Revenue multiple	20x	\$ 3.12	\$ 2.52
	25x	\$ 3.90	\$ 3.16

*Source: Dawson James Securities estimates*

This is not a straight shot for the company. The big tobacco companies will likely resist a mandate, try to push it to the right as far as possible, seek out the lowest-cost solution to comply and continue developing other nicotine delivery systems like IQOS.

The timeline for a mandate is probably 3-5 years. An NPRM will probably take 12-24 months from release to rulemaking and an additional 24- to 36-month transition time.

For now, we are valuing the CBD and KeyGene opportunities at \$100 million, or \$0.67 per share.

#### Price Target

Our \$7 price target is the sum of the estimated values of the VLN, non-addictive nicotine and hemp franchises. We attribute about \$3.08/share for the VLN asset. The non-addictive nicotine mandate is valued at \$3.18 per share. The remainder of the price target comprises the investment in the hemp business and the relationship with KeyGene.

#### Risk Analysis

The tobacco industry is highly regulated, and our price target depends on approval of the company's MRTP application and a nicotine mandate, which could be delayed or may not be approved. Our price target assumes the company will find a partner for the VLN business and this could take longer than estimated and/or the partner could demand different terms than assumed. The nicotine mandate may take longer to decide, and the transition period could be longer than estimated. There will likely be other paths attempted by the industry to comply or the industry may opt to focus on other nicotine delivery systems as regulation of the combustible cigarette market increases. This could affect our assumptions on the royalty rate as well as market share.

**Exhibit 1. Income Statement**

(\$ in 000s, except per-share data)

	2018	2019	2020	Q1 21 E	Q2 21 E	Q3 21 E	Q4 21 E	2021 E	2022 E
Revenue	\$ 26,426	\$ 25,833	\$ 28,111	\$ 7,250	\$ 7,250	\$ 7,250	\$ 7,250	\$ 29,000	\$ 30,000
Cost Of Goods Sold	25,527	25,818	26,673	6,720	6,720	6,720	6,720	26,880	27,000
Gross Profit	899	14	1,438	530	530	530	530	2,120	3,000
R&D	14,990	8,057	4,128	1,250	1,250	1,250	1,250	5,000	5,250
G&A	7,658	12,956	14,971	3,298	3,298	3,298	5,418	15,312	16,078
Impairment Charge	0	1,142	176	0	0	0	0	0	0
Sales & marketing	927	0	0	0	0	0	0	0	0
Depreciation & Amort.	1,342	1,425	1,346	349	349	349	349	1,396	1,396
Opex	24,918	23,581	20,621	4,897	4,897	4,897	7,017	21,708	22,724
Operating Income	\$ (24,019)	\$ (23,566)	\$ (19,183)	\$ (4,367)	\$ (4,367)	\$ (4,367)	\$ (6,487)	\$ (19,588)	\$ (19,724)
Other	14,945	(4,002)	(428)	0	0	0	0	0	0
Impairment Charge	49	0	(1,741)	0	0	0	0	0	0
Interest Income	1,069	1,066	1,751	223	307	274	240	1,044	538
Interest Expense	(11)	(56)	(72)	(18)	(18)	(18)	(18)	(72)	(72)
Pretax Income	(7,967)	(26,559)	(19,673)	(4,162)	(4,079)	(4,111)	(6,265)	(18,616)	(19,258)
Income Tax Expense	0	0	38	0	0	0	0	0	0
Net to Common	\$ (7,967)	\$ (26,559)	\$ (19,711)	\$ (4,162)	\$ (4,079)	\$ (4,111)	\$ (6,265)	\$ (18,616)	\$ (19,258)
Shares (000)	124,299	125,883	138,813	145,730	152,648	153,148	153,648	151,293	154,460
EPS	(\$0.06)	(\$0.21)	(\$0.14)	(\$0.03)	(\$0.03)	(\$0.03)	(\$0.04)	(\$0.12)	(\$0.12)
D&A	1,200	1,425	1,346	348	348	348	348	1,392	1,392
Stock Comp	3,187	3,540	1,654	492	492	492	492	1,968	2,066
Other	0	1,142	176	0	0	0	0	0	0
EBITDA	\$ (19,632)	\$ (17,459)	\$ (16,007)	\$ (3,527)	\$ (3,527)	\$ (3,527)	\$ (5,647)	\$ (16,228)	\$ (16,265)

 Source: 22<sup>nd</sup> Century Group, Inc. and Dawson James Securities estimates



**Exhibit 2. Balance Sheet and Cash Flow Statement**


(\$ in 000s)

	2018	2019	2020	2021 E	2022 E
Cash	605	485	1,029	1,029	1,029
Short-Term Investments	55,749	38,477	21,313	17,540	1,540
A/R	871	867	2,159	2,159	2,159
Inventory	3,044	2,266	2,034	2,034	2,034
Prepaid Exp.	928	648	1,806	1,806	1,806
<b>Total Current Assets</b>	<b>\$ 61,198</b>	<b>\$ 42,743</b>	<b>\$ 28,341</b>	<b>\$ 24,568</b>	<b>\$ 8,568</b>
PP&E	3,261	3,120	2,483	1,723	963
Operating Lease	0	602	247	247	247
Patent, Trademark, other intangibles	9,752	8,494	8,211	8,179	8,147
Equity Investment	3,092	8,403	6,536	6,536	6,536
Convertible Note Receivable	0	5,589	5,876	5,876	5,876
<b>Total Assets</b>	<b>\$ 77,302</b>	<b>\$ 68,951</b>	<b>\$ 51,694</b>	<b>\$ 47,129</b>	<b>\$ 30,337</b>
Bank Loans and N/P	689	581	539	539	539
Operating Lease	0	220	247	247	247
A/P	2,575	1,998	1,116	1,116	1,116
Accrued Expenses	1,826	2,619	4,830	4,830	4,830
Accrued Severance	0	359	339	339	339
Deferred Income	83	5	272	272	272
<b>Total Current Liabilities</b>	<b>\$ 5,174</b>	<b>\$ 5,780</b>	<b>\$ 7,343</b>	<b>\$ 7,343</b>	<b>\$ 7,343</b>
Long-Term Debt	848	292	0	0	0
Operating Lease	0	382	0	0	0
Accrued Severance	0	446	241	241	241
Shareholders' Equity	71,280	62,051	44,110	39,545	22,753
<b>Total Liabilities And Equity</b>	<b>\$ 77,302</b>	<b>\$ 68,951</b>	<b>\$ 51,694</b>	<b>\$ 47,129</b>	<b>\$ 30,337</b>
	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021 E</b>	<b>2022 E</b>
Net Income	(7,967)	(26,559)	(19,711)	(18,616)	(19,258)
Depreciation & Amort.	1,200	1,425	1,345	1,392	1,392
Stock Comp	3,187	3,540	1,654	1,968	2,066
Other	(14,618)	7,249	2,722	0	0
Working Capital	354	(242)	(1,631)	0	0
<b>Operating Cash Flow</b>	<b>\$ (17,844)</b>	<b>\$ (14,587)</b>	<b>\$ (15,621)</b>	<b>\$ (15,256)</b>	<b>\$ (15,799)</b>
Acquisition of Patents and trademarks	(657)	(515)	(468)	(500)	(500)
CapEx	(449)	(527)	(54)	(100)	(100)
Other	16,251	5,595	16,991	0	0
<b>Investing Activities</b>	<b>\$ 15,145</b>	<b>\$ 4,552</b>	<b>\$ 16,469</b>	<b>\$ (600)</b>	<b>\$ (600)</b>
Debt	(800)	(700)	(354)	0	0
Equity	445	10,616	50	12,083	400
Other	0	0	0	0	0
<b>Financing Activities</b>	<b>\$ (355)</b>	<b>\$ 9,916</b>	<b>\$ (304)</b>	<b>\$ 12,083</b>	<b>\$ 400</b>
Change in Cash	<b>(\$3,055)</b>	<b>(\$120)</b>	<b>\$ 544</b>	<b>(\$3,773)</b>	<b>(\$15,999)</b>

 Source: 22<sup>nd</sup> Century Group, Inc. and Dawson James Securities estimates

## **Important Disclosures:**

### **Price Chart:**



### **Price target and ratings changes over the past three years:**

Initiated – Buy – April 13, 2021 – Price Target \$7.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of March 31, 2021, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

**Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.**

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

	<b>Company Coverage</b>		<b>Investment Banking</b>	
<b>Ratings Distribution</b>	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	20	69%	6	30%
Market Perform (Neutral)	9	31%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	29	100%	6	21%

**Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.